Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

A number of other equities analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Monday.

Can-Fite BioPharma Stock Down 1.2 %

Can-Fite BioPharma stock opened at $1.60 on Friday. The stock has a market cap of $5.66 million, a PE ratio of -0.89 and a beta of 1.12. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The business’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.92.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.